Health Care

Fresenius Medical Care AG’s cash‑flow surge drives Citi’s €40 target, outpacing peers and showing disciplined growth amid Germany’s volatile market.

Danaher Corp. directors’ phantom‑share conversions revealed in SEC Form 4 filings—insider ownership, governance, and impact on shareholders explained.

Veeva Systems’ cloud platform for life‑science firms faces diverging investor sentiment amid AI‑driven tech volatility, with Burry calling it undervalued while analysts warn of margin risks—an essential read for investors evaluating niche software r…

West Pharmaceutical Services surges after strong Q1 earnings, citing cost‑efficient manufacturing, global expansion and new injection device tech—read why analysts see a “strong buy” trend.

McKesson’s 10‑year stock surge shows how robust pharma distribution boosts investor returns and improves drug safety, efficacy, and access for patients.

UHS Q1 2026 earnings show growth, higher revenue per admission, disciplined costs, and strong liquidity, positioning the company for continued expansion and shareholder returns.

Explore how United Therapeutics’ CEO trading plan reveals key insights into capital discipline, executive incentives, and regulatory compliance in the specialty‑pharma sector.

Amgen’s institutional investor confidence and DCF valuation reveal robust growth, efficient R&D spend, and a 21.5% profit margin, positioning the biotech firm favorably amid evolving value‑based reimbursement models.

Steris PLC’s modest Nasdaq gain reflects steady earnings, strong service contracts and a solid product pipeline, while highlighting the risks of supply‑chain costs, regulatory changes and competition in the infection‑control market.

Swedish Orphan Biovitrum (Sobi) tops Q1 expectations with double‑digit haemophilia and immunology growth, strong EBITDA, and a solid pipeline for future earnings momentum.